Cartesian Therapeutics Inc. Dividend Analysis

No. Cartesian Therapeutics (RNAC) does not pay a dividend, and no dividend payment appears anywhere in the filing history we hold.

It largely does not. Cartesian Therapeutics pays no dividend and we do not see a meaningful reduction in share count over the last twelve months, so cash is being retained in the business or spent on growth rather than returned. That is common for companies reinvesting heavily, and it means your return depends entirely on the share price.

Not currently. Cartesian Therapeutics's free cash flow is negative at -$79 million, meaning the business consumed cash over the period rather than generating it. A company funding a dividend from cash it is not producing would be paying shareholders out of its balance sheet or borrowings, which is not sustainable.

Our Healthcare sector page ranks the companies we cover by dividend score, which combines payout safety, free cash flow coverage and growth record. If income is what you are after, start there rather than with Cartesian Therapeutics.